Files in this item
National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic
Item metadata
dc.contributor.author | Palmateer, N. E. | |
dc.contributor.author | Dickson, E. | |
dc.contributor.author | Furrie, E. | |
dc.contributor.author | Godber, I. | |
dc.contributor.author | Goldberg, D. J. | |
dc.contributor.author | Gousias, P. | |
dc.contributor.author | Jarvis, L. | |
dc.contributor.author | Mathie, L. | |
dc.contributor.author | Mavin, S. | |
dc.contributor.author | McMenamin, J. | |
dc.contributor.author | McNeilly, T. N. | |
dc.contributor.author | Murcia, P. | |
dc.contributor.author | Murray, J. | |
dc.contributor.author | Reid, G. | |
dc.contributor.author | Robertson, C. | |
dc.contributor.author | Templeton, K. | |
dc.contributor.author | von Wissmann, B. | |
dc.contributor.author | Wallace, L. A. | |
dc.contributor.author | Waugh, C. | |
dc.contributor.author | McAuley, A. | |
dc.date.accessioned | 2022-09-27T12:30:08Z | |
dc.date.available | 2022-09-27T12:30:08Z | |
dc.date.issued | 2021-09 | |
dc.identifier | 280689080 | |
dc.identifier | d84e6ad9-a6c9-4d05-bd46-577228a9dc3a | |
dc.identifier | 85112532746 | |
dc.identifier | 34411992 | |
dc.identifier.citation | Palmateer , N E , Dickson , E , Furrie , E , Godber , I , Goldberg , D J , Gousias , P , Jarvis , L , Mathie , L , Mavin , S , McMenamin , J , McNeilly , T N , Murcia , P , Murray , J , Reid , G , Robertson , C , Templeton , K , von Wissmann , B , Wallace , L A , Waugh , C & McAuley , A 2021 , ' National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic ' , Public Health , vol. 198 , pp. 102-105 . https://doi.org/10.1016/j.puhe.2021.07.006 | en |
dc.identifier.issn | 0033-3506 | |
dc.identifier.other | ORCID: /0000-0002-1511-7944/work/116910278 | |
dc.identifier.uri | https://hdl.handle.net/10023/26078 | |
dc.description | This work was supported by the Scottish Government. | en |
dc.description.abstract | Objectives : Studies that measure the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (‘seroprevalence’) are essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic individuals. We aimed to measure seroprevalence in the Scottish population over the course of the COVID-19 pandemic – from before the first recorded case in Scotland through to the second pandemic wave. Study design : The study design of this study is serial cross sectional. Methods : We tested 41,477 residual samples retrieved from primary and antenatal care settings across Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (before rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in seroprevalence estimates and weekly SARS-CoV-2 notifications were compared. Results : Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the summer (range: 3%–5%) during a period of social restrictions, after which they increased concurrently with the second wave, reaching 9.6% (95% confidence interval [CI]: 8.4%–10.8%) in the week beginning 28th December in 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio [AOR]: 0.70, 95% CI: 0.61–0.79) and among individuals aged 20–39 years and 60 years and older (AOR: 0.74, 95% CI: 0.64–0.86; AOR: 0.80, 95% CI: 0.69–0.91, respectively) relative to those aged 0–19 years. Conclusions : After two waves of the COVID-19 pandemic, less than one in ten individuals in the Scottish population had antibodies to SARS-CoV-2. Seroprevalence may underestimate the true population exposure as a result of waning antibodies among individuals who were infected early in the first wave. | |
dc.format.extent | 4 | |
dc.format.extent | 311430 | |
dc.language.iso | eng | |
dc.relation.ispartof | Public Health | en |
dc.subject | Antibodies | en |
dc.subject | COVID-19 | en |
dc.subject | Cross sectional | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Seroprevalence | en |
dc.subject | RA0421 Public health. Hygiene. Preventive Medicine | en |
dc.subject | Public Health, Environmental and Occupational Health | en |
dc.subject | 3rd-DAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | NIS | en |
dc.subject.lcc | RA0421 | en |
dc.title | National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic | en |
dc.type | Journal article | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Education Division | en |
dc.identifier.doi | https://doi.org/10.1016/j.puhe.2021.07.006 | |
dc.description.status | Peer reviewed | en |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289625/ | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.